New research shows that lipid nanoparticles used in mRNA vaccines may deliver RNA more effectively when their structure is disorganised.

Leveraging its integrated "design-synthesis-quality control" system, Creative Biolabs is overcoming bottlenecks in mRNA ...

A new class of lipids improve the rates at which lipid nanoparticles (LNPs) successfully deliver RNA therapeutics and gene editing tools, promising to increase their effectiveness of such treatments.

Researchers at the Icahn School of Medicine at Mount Sinai say they have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection, a ...

Imagine a breakthrough in cancer treatment where only malignant cells are targeted, sparing healthy host cells; or patients with abnormal protein synthesis are treated to produce a healthy protein.

Imagine a cancer treatment that precisely targets malignant cells, leaving healthy ones untouched. Consider, also, a cancer treatment that corrects abnormal protein synthesis to produce healthy ...

The FDA declined to review Moderna's mRNA influenza vaccine due to inadequate clinical trial comparators for older adults.